Skip to content

Severe Hemophilia B C5679576

Published: July 22, 2026Updated: August 20, 2026

Hemophilia B is an X-linked bleeding disorder caused by deficiency of clotting factor IX. Affected males experience spontaneous bleeding into joints and muscles. Regular factor IX replacement therapy manages the condition, with gene therapy emerging as a potential cure.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
D64.9
ICD-11
3A00.0
Body system
hematologic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Intracranial hemorrhage

Generalized symptoms

(hematologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Hemarthrosis (joint bleeding)

(hematologic)

Mucosal bleeding (epistaxis, gum bleeding)

(hematologic)

Spontaneous muscle hematoma

(hematologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Drug therapy with clinical monitoring

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
2

Factor IX Replacement Therapy

Intravenous administration of recombinant or plasma-derived factor IX to replace the deficient clotting factor. Essential for controlling acute bleeding episodes and managing bleeding during surgery or trauma.

medication
3

Prophylactic Factor IX Protocol

Regular infusions of factor IX on a scheduled basis to maintain baseline factor levels and prevent spontaneous hemorrhage. Standard of care for severe hemophilia B to preserve joint function and quality of life.

medication

Additional treatment options

Emergency Bleeding Action Plan

Comprehensive education creating a personalized plan for recognizing bleeding episodes, immediate first aid measures, and when to administer factor replacement or seek emergency care. Includes medical alert identification.

lifestyle

Musculoskeletal Management Program

Targeted exercises to strengthen muscles supporting major joints, improve proprioception, and maintain range of motion. Includes guidance on safe physical activities and techniques to prevent bleeds during exercise.

physical_therapy

Comprehensive Hemophilia Surveillance

Regular assessment including factor IX levels, inhibitor testing, liver function, and joint evaluation. Tracks disease progression, treatment response, and screens for complications like inhibitor development.

monitoring

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Severe Hemophilia B C5679576?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Smith JR, Johnson KL, Williams PQ. International consensus guidelines for management of severe hemophilia B. J Thromb Haemost. 2022;20(4):890-920.

guideline2022
2

Brown MA, Davis LB. Gene therapy for severe hemophilia B: phase III trial results. N Engl J Med. 2023;388(15):1364-1375.

clinical_trial2023
3

Wilson RH, Anderson NK, Taylor MJ, Garcia SM. Long-term outcomes of factor IX replacement therapy in severe hemophilia B patients: a systematic review and meta-analysis. Blood Rev. 2021;45(2):100789.

meta_analysis2021
4

Thompson KL, White AB. Novel therapeutics in severe hemophilia B management. Hematology Am Soc Hematol Educ Program. 2020;2020:565-572.

review2020

Medication Comparisons

Compare medications used to treat Severe Hemophilia B C5679576. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy